ORION CORPORATION STOCK EXCHANGE RELEASE 20 October 2010 AT 4.15 PM EET
Orion Corporation has submitted a marketing authorisation application for the intensive care sedative agent dexmedetomidine for the evaluation by the European Medicines Agency (EMA), the pharmaceutical regulatory authority for the EU countries. EMA has announced today that it has validated the centralised marketing authorisation application and initiated the review. The review time for a centralised marketing authorisation application typically exceeds one year.
Orion Corporation
Timo Lappalainen Reijo Salonen
President and CEO SVP, Research and Development
Contact person:
Reijo Salonen, SVP, Research and Development, phone +358 50 966 3647
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi